Radiopharmaceuticals for renal studies

L. Rao Chervu, Leonard M. Freeman, M. Donald Blaufox

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

A review of the wide spectrum of radiopharmaceuticals developed over the last 15 yr for application in the evaluation of diseases of the kidney and urinary tract is presented below. The radiolabeled contrast agents including Hippuran have been extensively applied for renal function assessment. The kinetics of clearance of many of these agents are not yet satisfactorily established, and there is no ideal agent for routine clinical application, particularly by external counting methods. Many agents for intrarenal blood flow measurement have been reported that have yet to be adapted for obtaining clinical information. Renal morphology has been studied using several radiopharmaceuticals that are either fixed in the renal tubules for a sufficiently long time (chlormerodrin, 99mTc-Fe ascorbic acid) or cleared from the kidneys fairly rapidly (Hippuran). These agents suffer from several disadvantages because of suboptimum energy of the radiolabel for use with imaging equipment, or relatively high radiation dose, or slow rate of excretion with inadequate organ specificity. It is hoped that the development of new radiopharmaceuticals tagged with radionuclides that have ideal imaging characteristics (99mTc or 111In) and satisfactory renal clearances will provide a major breakthrough in the continuing search for satisfactory renal agents for imaging and function tests in the near future.

Original languageEnglish (US)
Pages (from-to)3-22
Number of pages20
JournalSeminars in Nuclear Medicine
Volume4
Issue number1
DOIs
StatePublished - 1974

Fingerprint

Radiopharmaceuticals
Kidney
Chlormerodrin
Renal Agents
Urologic Diseases
Organ Specificity
Radioisotopes
Contrast Media
Ascorbic Acid
Radiation
Equipment and Supplies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Radiopharmaceuticals for renal studies. / Rao Chervu, L.; Freeman, Leonard M.; Donald Blaufox, M.

In: Seminars in Nuclear Medicine, Vol. 4, No. 1, 1974, p. 3-22.

Research output: Contribution to journalArticle

Rao Chervu, L. ; Freeman, Leonard M. ; Donald Blaufox, M. / Radiopharmaceuticals for renal studies. In: Seminars in Nuclear Medicine. 1974 ; Vol. 4, No. 1. pp. 3-22.
@article{98e974fb64fa4604866c6fb08346dba8,
title = "Radiopharmaceuticals for renal studies",
abstract = "A review of the wide spectrum of radiopharmaceuticals developed over the last 15 yr for application in the evaluation of diseases of the kidney and urinary tract is presented below. The radiolabeled contrast agents including Hippuran have been extensively applied for renal function assessment. The kinetics of clearance of many of these agents are not yet satisfactorily established, and there is no ideal agent for routine clinical application, particularly by external counting methods. Many agents for intrarenal blood flow measurement have been reported that have yet to be adapted for obtaining clinical information. Renal morphology has been studied using several radiopharmaceuticals that are either fixed in the renal tubules for a sufficiently long time (chlormerodrin, 99mTc-Fe ascorbic acid) or cleared from the kidneys fairly rapidly (Hippuran). These agents suffer from several disadvantages because of suboptimum energy of the radiolabel for use with imaging equipment, or relatively high radiation dose, or slow rate of excretion with inadequate organ specificity. It is hoped that the development of new radiopharmaceuticals tagged with radionuclides that have ideal imaging characteristics (99mTc or 111In) and satisfactory renal clearances will provide a major breakthrough in the continuing search for satisfactory renal agents for imaging and function tests in the near future.",
author = "{Rao Chervu}, L. and Freeman, {Leonard M.} and {Donald Blaufox}, M.",
year = "1974",
doi = "10.1016/S0001-2998(74)80020-6",
language = "English (US)",
volume = "4",
pages = "3--22",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Radiopharmaceuticals for renal studies

AU - Rao Chervu, L.

AU - Freeman, Leonard M.

AU - Donald Blaufox, M.

PY - 1974

Y1 - 1974

N2 - A review of the wide spectrum of radiopharmaceuticals developed over the last 15 yr for application in the evaluation of diseases of the kidney and urinary tract is presented below. The radiolabeled contrast agents including Hippuran have been extensively applied for renal function assessment. The kinetics of clearance of many of these agents are not yet satisfactorily established, and there is no ideal agent for routine clinical application, particularly by external counting methods. Many agents for intrarenal blood flow measurement have been reported that have yet to be adapted for obtaining clinical information. Renal morphology has been studied using several radiopharmaceuticals that are either fixed in the renal tubules for a sufficiently long time (chlormerodrin, 99mTc-Fe ascorbic acid) or cleared from the kidneys fairly rapidly (Hippuran). These agents suffer from several disadvantages because of suboptimum energy of the radiolabel for use with imaging equipment, or relatively high radiation dose, or slow rate of excretion with inadequate organ specificity. It is hoped that the development of new radiopharmaceuticals tagged with radionuclides that have ideal imaging characteristics (99mTc or 111In) and satisfactory renal clearances will provide a major breakthrough in the continuing search for satisfactory renal agents for imaging and function tests in the near future.

AB - A review of the wide spectrum of radiopharmaceuticals developed over the last 15 yr for application in the evaluation of diseases of the kidney and urinary tract is presented below. The radiolabeled contrast agents including Hippuran have been extensively applied for renal function assessment. The kinetics of clearance of many of these agents are not yet satisfactorily established, and there is no ideal agent for routine clinical application, particularly by external counting methods. Many agents for intrarenal blood flow measurement have been reported that have yet to be adapted for obtaining clinical information. Renal morphology has been studied using several radiopharmaceuticals that are either fixed in the renal tubules for a sufficiently long time (chlormerodrin, 99mTc-Fe ascorbic acid) or cleared from the kidneys fairly rapidly (Hippuran). These agents suffer from several disadvantages because of suboptimum energy of the radiolabel for use with imaging equipment, or relatively high radiation dose, or slow rate of excretion with inadequate organ specificity. It is hoped that the development of new radiopharmaceuticals tagged with radionuclides that have ideal imaging characteristics (99mTc or 111In) and satisfactory renal clearances will provide a major breakthrough in the continuing search for satisfactory renal agents for imaging and function tests in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0015967775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015967775&partnerID=8YFLogxK

U2 - 10.1016/S0001-2998(74)80020-6

DO - 10.1016/S0001-2998(74)80020-6

M3 - Article

VL - 4

SP - 3

EP - 22

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 1

ER -